Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914479 · ClinicalTrials.gov registry record · Phase 1
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
A Phase 1 study of Recurrent Malignant Brain Neoplasm and Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06914479 is a Phase 1 study of Recurrent Malignant Brain Neoplasm and Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06914479, a Phase 1 study of Recurrent Malignant Brain Neoplasm and Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (resectable) and that have come back after a period of improvement (recurrent). AdV-HSV1-TK and AdV-Flt3L use a virus modified in the laboratory to kill tumor cells and stimulate the immune system to recognize the tumor cells as "invaders" which can lead to tumor shrinkage. For this process to work, an oral anti-herpes medication called valacyclovir is also needed. Giving AdV-HSV1-TK, AdV-Flt3L and valacyclovir may be safe, tolerable and/or effective in treating patients with resectable, recurrent primary malignant brain tumors.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- GENETIC Ad-hCMV-Flt3L
- GENETIC Ad-hCMV-TK
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2031-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06914479
The ClinicalTrials.gov registry entry for NCT06914479 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Malignant Brain Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06914479 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06914479 about?
NCT06914479 is a clinical study titled "Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors". This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (resectable) and that have come back after a period of improvemen...
What is the current status of trial NCT06914479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2026-06-01. Estimated completion is 2031-06-01.
What conditions does trial NCT06914479 study?
This clinical trial studies the following conditions: Recurrent Malignant Brain Neoplasm, Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Resectable Brain Neoplasm.
What interventions are being tested in trial NCT06914479?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), Ad-hCMV-Flt3L (GENETIC), Ad-hCMV-TK (GENETIC).
Who is sponsoring clinical trial NCT06914479?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914479 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Malignant Brain Neoplasm
All registered trials for this condition
Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.